Composition for the treatment of knee osteo-arthritis
Treatment able to act both on the symptomatology of arthrosic pathology, and on the pathogenetic mechanisms underlying the genesis and perpetuation of the disease. These aspects highlight it as an innovative treatment with significant applications given the incidence of osteoarthritis in the global population.
The compound is configured as a treatment able to act both on the symptomatology of arthrosic pathology and on the pathogenetic mechanisms underlying the genesis and perpetuation of the same. These aspects highlight the compound as an innovative treatment with significant applications given the incidence of osteoarthritis in the global population. Furthermore, the formulation of a solution composed of hyaluronic acid and sodium chromoglycate represents an absolute novelty in the pharmaceutical sector. Formulations of hyaluronic acid in association with other compounds (chondroitin-sulphate, mannitol, triamcinolone) are also already on the market demonstrating the need for the implementation of infiltrative therapy and the tendency of pharmaceutical companies to work in this direction. The new compound was formulated with the intent to make it administrable by intra-articular route and has the advantage of longer duration of the lubricating effect of hyaluronic acid and greater local concentration of the drug that allows the permanence of the sodium chromoglycate in the joint for a longer time, increasing the effectiveness of the treatment; besides the therapeutic effect, the sodium chromoglycate allows to act also on the genesis of the arthrosic pathology.
- Medical treatments;
- Osteoarthritis of the knee;
- Knee infiltration.
- Method of administration that maximizes the effectiveness of the drug;
- Enhanced component effect: the compound uses a synergistic action of its individual components;
- The compound not only has an anti-inflammatory action, but also has prevention on the genesis of arthrosic pathology.